After treatment with gonadotropin, clomiphene, or letrozole, clinical pregnancies occurred in 35.5%, 28.3%, and 22.4% of cycles, and live birth in 32.2%, 23.3%, and 18.7%, respectively; pregnancy ...

The drug letrozole, which suppresses estrogen production, cut the risk of breast cancer recurrence nearly in half for older women who had already taken the standard tamoxifen treatment ...

Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. New England Journal of Medicine , 2014; 371 (2): 119 DOI: 10.1056/NEJMoa1313517 Cite This Page : ...

The drug letrozole results in higher birth rates in women with polycystic ovary syndrome (PCOS) than the current preferred infertility treatment drug, according to a nationwide study led by Penn ...

Letrozole is a more potent inhibitor of aromatase than anastrozole, and at their conventionally used doses, letrozole leads to more complete inhibition of whole-body aromatase (> 99% compared with 97% ...

A 750-women government-funded study, one of the largest to date looking at infertility and PCOS, found that the drug letrozole improves ovulation and results in higher pregnancy and live ...

A letrozole pill once a week restored fertility in obese, infertile men and led to their partners giving birth to two full-term, healthy babies, according to a new study from Canada.

Letrozole may be considered the drug of choice for women with a higher risk of breast cancer recurrence. In addition, women who have concerns about endometrial cancer may also be advised to ...

A total of 5187 women were enrolled (median follow-up, 2.4 years). At the first interim analysis, there were 207 local or metastatic recurrences of breast cancer or new primary cancers in the ...

A letrozole pill once a week restored fertility in obese, infertile men and led to their partners giving birth to two full-term, healthy babies, according to a new study from Canada. The results ...

Lidia Schapira provides her perspective on a recent study of palbociclib plus letrozole as neoadjuvant therapy for postmenopausal women with ER-positive breast cancer.